How do I install the Endo Avoid Sympathomimetic Cvd skill?

Run npx skillmds@latest add dromlakhani/endo-avoid-sympathomimetic-cvd in your terminal (requires Node.js), paste this page's agent-chat prompt into Claude, Cursor, or any MCP-connected agent, or download the SKILL.md file and copy it into your agent's skills directory.

Is Endo Avoid Sympathomimetic Cvd safe to use?

This skill has not completed SkillMD's automated safety review yet. Independent scanners report: SkillSpector: PASS, Skill Scanner: PASS. Capability flags: docs only. SkillMD never runs a skill's scripts for you; review the SKILL.md before installing.

Which AI agents work with Endo Avoid Sympathomimetic Cvd?

This skill is tagged as working with Claude Code, Claude.ai, OpenAI Codex. SKILL.md is an open format, so most agents that read a skills directory can load it too.

Is Endo Avoid Sympathomimetic Cvd free to use?

Yes. Installing skills from SkillMD is free, and the skill stays under its author's original license.

Who published Endo Avoid Sympathomimetic Cvd?

dromlakhani (@dromlakhani) published this skill. Their other Agent Skills are listed on their SkillMD profile.

Endo Avoid Sympathomimetic Cvd by dromlakhani

Name: Endo Avoid Sympathomimetic Cvd
Rating: 4.666666666666667 (3 reviews)
Author: dromlakhani

Endo Avoid Sympathomimetic Cvd

Recommends using non‑sympathomimetic agents (lorcaserin, orlistat) for pharmacological weight loss in patients with cardiovascular disease. Triggers include clinician questions such as “What weight‑loss medication is safest for this patient with coronary artery disease?” or “Should I avoid phentermine in a patient with prior stroke seeking obesity treatment?”.

dromlakhani Updated Sep 8, 2026 10 repo stars

File contents

Avoid sympathomimetics in CVD for weight loss

STEP 1 — Gather Information

Determine presence of cardiovascular disease (CAD, prior stroke, heart failure, PAD) or uncontrolled hypertension/history of heart disease; assess BMI ≥27 kg/m² with comorbidity or ≥30 kg/m²; review current medications for sympathomimetic contraindications (MAOIs, SSRIs) and obtain baseline weight, BP, heart rate.

STEP 2 — Rule In / Rule Out

If patient has CVD (or uncontrolled hypertension/history of heart disease) and is seeking pharmacological weight loss → proceed; otherwise, standard weight‑loss medication selection applies.

STEP 3 — Classify or Stratify

Choose lorcaserin if no concomitant serotonergic drugs (SSRI/SNRI/MAOI/triptan) and no psychiatric contraindications; otherwise select orlistat if no chronic malabsorption, cholestasis, pregnancy, or breastfeeding.

STEP 4 — Decide

Prescribe lorcaserin 10 mg BID or orlistat 120 mg TID as adjunct to lifestyle modification; document avoidance of phentermine/diethylpropion and arrange monthly follow‑up for efficacy and safety.

Clinical Guardrails / Mimics / Pitfalls

Do not prescribe sympathomimetics (phentermine, diethylpropion) in CVD; avoid lorcaserin with serotonergic agents due to serotonin syndrome risk; avoid orlistat in patients with chronic malabsorption, cholestasis, pregnancy, or breastfeeding; monitor BP and heart rate; ensure concurrent diet, exercise, and behavioral therapy.

Concrete Clinical Example

A 60‑year‑old woman with prior ischemic stroke (BMI 31) asks for weight‑loss aid; she takes atorvastatin and aspirin, no antidepressants. After confirming CVD and no serotonergic meds, orlistat 120 mg TID is started; phentermine is avoided due to stroke history.

Source: Pharmacological Management of Obesity: An Endocrine Society Clinical Practice Guideline, Endocrine Society, 2015, DOI:10.1210/jc.2014-3415

---name: endo-avoid-sympathomimetic-cvddescription: Recommends using non‑sympathomimetic agents (lorcaserin, orlistat) for pharmacological weight loss in patients with cardiovascular disease. Triggers include clinician questions such as “What weight‑loss medication is safest for this patient with coronary artery disease?” or “Should I avoid phentermine in a patient with prior stroke seeking obesity treatment?”.---# Avoid sympathomimetics in CVD for weight loss## STEP 1 — Gather InformationDetermine presence of cardiovascular disease (CAD, prior stroke, heart failure, PAD) or uncontrolled hypertension/history of heart disease; assess BMI ≥27 kg/m² with comorbidity or ≥30 kg/m²; review current medications for sympathomimetic contraindications (MAOIs, SSRIs) and obtain baseline weight, BP, heart rate.## STEP 2 — Rule In / Rule OutIf patient has CVD (or uncontrolled hypertension/history of heart disease) and is seeking pharmacological weight loss → proceed; otherwise, standard weight‑loss medication selection applies.## STEP 3 — Classify or StratifyChoose lorcaserin if no concomitant serotonergic drugs (SSRI/SNRI/MAOI/triptan) and no psychiatric contraindications; otherwise select orlistat if no chronic malabsorption, cholestasis, pregnancy, or breastfeeding.## STEP 4 — DecidePrescribe lorcaserin 10 mg BID or orlistat 120 mg TID as adjunct to lifestyle modification; document avoidance of phentermine/diethylpropion and arrange monthly follow‑up for efficacy and safety.## Clinical Guardrails / Mimics / PitfallsDo not prescribe sympathomimetics (phentermine, diethylpropion) in CVD; avoid lorcaserin with serotonergic agents due to serotonin syndrome risk; avoid orlistat in patients with chronic malabsorption, cholestasis, pregnancy, or breastfeeding; monitor BP and heart rate; ensure concurrent diet, exercise, and behavioral therapy.## Concrete Clinical ExampleA 60‑year‑old woman with prior ischemic stroke (BMI 31) asks for weight‑loss aid; she takes atorvastatin and aspirin, no antidepressants. After confirming CVD and no serotonergic meds, orlistat 120 mg TID is started; phentermine is avoided due to stroke history.**Source:** Pharmacological Management of Obesity: An Endocrine Society Clinical Practice Guideline, Endocrine Society, 2015, DOI:10.1210/jc.2014-3415

Frequently asked questions